CARDIOVASCULAR JOURNAL OF AFRICA • Volume 25, No 2, March/April 2014
92
AFRICA
For full prescribing information, refer to the pack-
age insert approved by the Medicines Regulatory
Authority (MCC).
S4 XARELTO
®
10 (Film-coated tablets). Reg.
No.: 42/8.2/1046. Each film-coated tablet contains
rivaroxaban 10 mg. PHARMACOLOGICAL
CLASSIFICATION: A.8.2 Anticoagulants.
INDICATION: Prevention of venous thrombo-
embolism (VTE) in patients undergoing major
orthopaedic surgery of the lower limbs.
S4 XARELTO
®
15 and XARELTO
®
20
(Film-coated tablets). Reg. No.: XARELTO® 15:
46/8.2/0111; XARELTO® 20: 46/8.2/0112. Each
film-coated tablet contains rivaroxaban 15 mg
(XARELTO
®
15 ) or 20 mg (XARELTO
®
20).
PHARMACOLOGICAL CLASSIFICATION:
A.8.2 Anticoagulants. INDICATIONS: (1)
Prevention of stroke and systemic embolism
in patients with non-valvular atrial fibrillation
(SPAF); (2) Treatment of deep-vein thrombosis
(DVT) and for the prevention of recurrent deep-
vein thrombosis (DVT) and pulmonary embolism
(PE); (3) Treatment of pulmonary embolism
(PE) and for the prevention of recurrent pulmo-
nary embolism (PE) and deep-vein thrombo-
sis (DVT). HCR: Bayer (Pty) Ltd, Reg. No.:
1968/011192/07, 27 Wrench Road, Isando, 1609.
Tel: 011 921 5044. Fax: 011 921 5041.
L.ZA.GM.10.2013.0821
Forward-looking statements
This release may contain forward-looking state-
ments based on current assumptions and forecasts
made by Bayer group or subgroup management.
Various known and unknown risks, uncertainties
and other factors could lead to material differ-
ences between the actual future results, financial
situation, development or performance of the
company and the estimates given here. These
factors include those discussed in Bayer’s public
reports which are available on the Bayer website
at
The company assumes no
liability whatsoever to update these forward-
looking statements or to conform them to future
events or developments.
Call for
Articles
This peer-reviewed journal is available as full text at all tertiary institutions in
South Africa, presenting a great opportunity to submit your
good-quality original articles for speedy publication.
Recent user research has shown that some 10 000 annual topic searches
were done on the
SA Journal of Diabetes & Vascular Disease
database,
which contains seven years of published material.
The
SA Journal of Diabetes & Vascular Disease
aims to provide a forum for
specialists involved in the care of people with diabetes, to exchange information,
promote better management and stimulate research in Africa.
This quarterly journal publishes original research and scholarly reviews about
prevention and management of diabetes, relating to both general and specific issues.
The
SA Journal of Diabetes & Vascular Disease
invites you to submit
your articles online only. Read the Instructions to Authors at
for more information on the journal’s policies and the submission process.
I
N
S
U
L
I
N
R
E
S
I
S
T
A
N
C
E
O
B
E
S
I
T
Y
H
Y
P
E
R
T
E
N
S
I
O
N
D
Y
S
L
I
P
I
D
A
E
M
I
A
T
H
R
O
M
B
O
S
I
S
A
T
H
E
R
O
S
C
L
E
R
O
S
I
S
H
Y
P
E
R
G
L
Y
C
A
E
M
I
A
H
Y
P
E
R
I
N
S
U
L
I
N
A
E
M
I
A
D
I
A
B
E
T
E
S
&
V
A
S
C
U
L
A
R
D
I
S
E
A
S
E
